Corticostriatal synaptic adaptations in Huntington's disease

Current Opinion in Neurobiology

Volumn 33, Issue , 2015, Pages 53-62

  Plotkin, Joshua L ^a   Surmeier, D James ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED GROWTH FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR;

CELL FUNCTION; CELL POPULATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; FUNCTIONAL ASSESSMENT; GABAERGIC TRANSMISSION; HUMAN; HUNTINGTON CHOREA; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NERVE CELL; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SPINY PROJECTION NEURON; SYNAPTIC DYSFUNCTION; SYNAPTIC TRANSMISSION; ADAPTATION; ANIMAL; BRAIN CORTEX; CORPUS STRIATUM; DEFICIENCY; GENETICS; KNOCKOUT MOUSE; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPSE;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CEREBRAL CORTEX; CORPUS STRIATUM; HUMANS; HUNTINGTON DISEASE; MICE; MICE, KNOCKOUT; SYNAPSES;

EID: 84923039287     PISSN: 09594388     EISSN: 18736882     Source Type: Journal    
DOI: 10.1016/j.conb.2015.01.020     Document Type: Review

References (84)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
2. Menalled L.B., Chesselet M.F. Mouse models of Huntington's disease. Trends Pharmacol Sci 2002, 23:32-39.
3. Cepeda C., Wu N., Andre V.M., Cummings D.M., Levine M.S. The corticostriatal pathway in Huntington's disease. Prog Neurobiol 2007, 81:253-271.
4. Zuccato C., Valenza M., Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010, 90:905-981.
5. Berardelli A., Noth J., Thompson P.D., Bollen E.L., Curra A., Deuschl G., van Dijk J.G., Topper R., Schwarz M., Roos R.A. Pathophysiology of chorea and bradykinesia in Huntington's disease. Mov Disord 1999, 14:398-403.
6. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985, 44:559-577.
7. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 1988, 85:5733-5737.
8. Vonsattel J.P., Keller C., Cortes Ramirez E.P. Huntington's disease - neuropathology. Handb Clin Neurol 2011, 100:83-100.
9. Gerfen C.R., Surmeier D.J. Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 2011, 34:441-466.
10. Jones L., Hughes A. Pathogenic mechanisms in Huntington's disease. Int Rev Neurobiol 2011, 98:373-418.
11. Parsons M.P., Raymond L.A. Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron 2014, 82:279-293.
12. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986, 321:168-171.
13. Koh J.Y., Peters S., Choi D.W. Neurons containing NADPH-diaphorase are selectively resistant to quinolinate toxicity. Science 1986, 234:73-76.
14. Deng Y.P., Wong T., Bricker-Anthony C., Deng B., Reiner A. Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice. Neurobiol Dis 2013, 60:89-107.
15. Deng Y.P., Wong T., Wan J.Y., Reiner A. Differential loss of thalamostriatal and corticostriatal input to striatal projection neuron types prior to overt motor symptoms in the Q140 knock-in mouse model of Huntington's disease. Front Syst Neurosci 2014, 8:198.
16. Altar C.A., Cai N., Bliven T., Juhasz M., Conner J.M., Acheson A.L., Lindsay R.M., Wiegand S.J. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997, 389:856-860.
17. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 2009, 5:311-322.
18. Jia Y., Gall C.M., Lynch G. Presynaptic BDNF promotes postsynaptic long-term potentiation in the dorsal striatum. J Neurosci 2010, 30:14440-14445.
19. Nithianantharajah J., Hannan A.J. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease. Neuroscience 2013, 251:66-74.
20. Zuccato C., Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 2007, 81:294-330.
21. Raymond L.A., Andre V.M., Cepeda C., Gladding C.M., Milnerwood A.J., Levine M.S. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience 2011, 198:252-273.
22. Chen J.Y., Wang E.A., Cepeda C., Levine M.S. Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility. Front Neurosci 2013, 7:114.
23. Estrada-Sanchez A.M., Rebec G.V. Role of cerebral cortex in the neuropathology of Huntington's disease. Front Neural Circuits 2013, 7:19.
24. Pouladi M.A., Morton A.J., Hayden M.R. Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci 2013, 14:708-721.
25. Levine M.S., Cepeda C., Hickey M.A., Fleming S.M., Chesselet M.F. Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci 2004, 27:691-697.
26. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
27. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23:181-192.
28. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.Z., et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 2003, 12:1555-1567.
29. Gray M., Shirasaki D.I., Cepeda C., Andre V.M., Wilburn B., Lu X.H., Tao J., Yamazaki I., Li S.H., Sun Y.E., et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 2008, 28:6182-6195.
30. Menalled L.B., Sison J.D., Dragatsis I., Zeitlin S., Chesselet M.F. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 2003, 465:11-26.
31. 1H MRS in zQ175 knock-in mouse model of Huntington's disease. PLoS ONE 2012, 7:e50717.
32. Menalled L.B., Kudwa A.E., Miller S., Fitzpatrick J., Watson-Johnson J., Keating N., Ruiz M., Mushlin R., Alosio W., McConnell K., et al. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. PLoS ONE 2012, 7:e49838.
33. Cepeda C., Hurst R.S., Calvert C.R., Hernandez-Echeagaray E., Nguyen O.K., Jocoy E., Christian L.J., Ariano M.A., Levine M.S. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 2003, 23:961-969.
34. Kravitz A.V., Freeze B.S., Parker P.R., Kay K., Thwin M.T., Deisseroth K., Kreitzer A.C. Regulation of Parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 2010, 466:622-626.
35. Andre V.M., Cepeda C., Fisher Y.E., Huynh M., Bardakjian N., Singh S., Yang X.W., Levine M.S. Differential electrophysiological changes in striatal output neurons in Huntington's disease. J Neurosci 2011, 31:1170-1182.
36. Cepeda C., Galvan L., Holley S.M., Rao S.P., Andre V.M., Botelho E.P., Chen J.Y., Watson J.B., Deisseroth K., Levine M.S. Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models. J Neurosci 2013, 33:7393-7406.
37. Plotkin J.L., Day M., Peterson J.D., Xie Z., Kress G.J., Rafalovich I., Kondapalli J., Gertler T.S., Flajolet M., Greengard P., et al. Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease. Neuron 2014, 83:178-188.
38. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 2010, 11:682-696.
39. Milnerwood A.J., Gladding C.M., Pouladi M.A., Kaufman A.M., Hines R.M., Boyd J.D., Ko R.W., Vasuta O.C., Graham R.K., Hayden M.R., et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010, 65:178-190.
40. Gladding C.M., Sepers M.D., Xu J., Zhang L.Y., Milnerwood A.J., Lombroso P.J., Raymond L.A. Calpain and striatal-enriched protein tyrosine phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse model. Hum Mol Genet 2012, 21:3739-3752.
41. Botelho E.P., Wang E., Chen J.Y., Holley S., Andre V., Cepeda C., Levine M.S. Differential synaptic and extrasynaptic glutamate-receptor alterations in striatal medium-sized spiny neurons of aged YAC128 Huntington's disease mice. PLoS Curr 2014, 6.
42. Bergles D.E., Diamond J.S., Jahr C.E. Clearance of glutamate inside the synapse and beyond. Curr Opin Neurobiol 1999, 9:293-298.
43. Miller B.R., Dorner J.L., Shou M., Sari Y., Barton S.J., Sengelaub D.R., Kennedy R.T., Rebec G.V. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 2008, 153:329-337.
44. Tong X., Ao Y., Faas G.C., Nwaobi S.E., Xu J., Haustein M.D., Anderson M.A., Mody I., Olsen M.L., Sofroniew M.V., et al. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. Nat Neurosci 2014, 17:694-703.
45. Gladding C.M., Fan J., Zhang L.Y., Wang L., Xu J., Li E.H., Lombroso P.J., Raymond L.A. Alterations in striatal-enriched protein tyrosine phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model. J Neurochem 2014, 130:145-159.
46. Marco S., Giralt A., Petrovic M.M., Pouladi M.A., Martinez-Turrillas R., Martinez-Hernandez J., Kaltenbach L.S., Torres-Peraza J., Graham R.K., Watanabe M., et al. Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models. Nat Med 2013, 19:1030-1038.
47. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.
48. Gauthier L.R., Charrin B.C., Borrell-Pages M., Dompierre J.P., Rangone H., Cordelieres F.P., De Mey J., MacDonald M.E., Lessmann V., Humbert S., et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118:127-138.
49. Freeman A.Y., Soghomonian J.J., Pierce R.C. Tyrosine kinase B and C receptors in the neostriatum and nucleus accumbens are co-localized in enkephalin-positive and enkephalin-negative neuronal profiles and their expression is influenced by cocaine. Neuroscience 2003, 117:147-156.
50. Kress G.J., Yamawaki N., Wokosin D.L., Wickersham I.R., Shepherd G.M., Surmeier D.J. Convergent cortical innervation of striatal projection neurons. Nat Neurosci 2013, 16:665-667.
51. Brito V., Puigdellivol M., Giralt A., del Toro D., Alberch J., Gines S. Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies. Cell Death Dis 2013, 4:e595.
52. Deyts C., Galan-Rodriguez B., Martin E., Bouveyron N., Roze E., Charvin D., Caboche J., Betuing S. Dopamine D2 receptor stimulation potentiates polyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho/ROCK-II activation. PLoS ONE 2009, 4:e8287.
53. Ji J., Sundquist K., Sundquist J. Cancer incidence in patients with polyglutamine diseases: a population-based study in Sweden. Lancet Oncol 2012, 13:642-648.
54. Kozorovitskiy Y., Saunders A., Johnson C.A., Lowell B.B., Sabatini B.L. Recurrent network activity drives striatal synaptogenesis. Nature 2012, 485:646-650.
55. Gu X., Li C., Wei W., Lo V., Gong S., Li S.H., Iwasato T., Itohara S., Li X.J., Mody I., et al. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 2005, 46:433-444.
56. Greenberg M.E., Xu B., Lu B., Hempstead B.L. New insights in the biology of BDNF synthesis and release: implications in CNS function. J Neurosci 2009, 29:12764-12767.
57. Park H., Popescu A., Poo M.M. Essential role of presynaptic NMDA receptors in activity-dependent BDNF secretion and corticostriatal LTP. Neuron 2014, 84:1009-1022.
58. Lynch G., Kramar E.A., Rex C.S., Jia Y., Chappas D., Gall C.M., Simmons D.A. Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease. J Neurosci 2007, 27:4424-4434.
59. Cepeda C., Starling A.J., Wu N., Nguyen O.K., Uzgil B., Soda T., Andre V.M., Ariano M.A., Levine M.S. Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. J Neurosci Res 2004, 78:855-867.
60. Cummings D.M., Cepeda C., Levine M.S. Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease. ASN Neuro 2010, 2:e00036.
61. Andre V.M., Fisher Y.E., Levine M.S. Altered balance of activity in the striatal direct and indirect pathways in mouse models of Huntington's disease. Front Syst Neurosci 2011, 5:46.
62. Dvorzhak A., Semtner M., Faber D.S., Grantyn R. Tonic mGluR5/CB1-dependent suppression of inhibition as a pathophysiological hallmark in the striatum of mice carrying a mutant form of huntingtin. J Physiol 2013, 591:1145-1166.
63. Adermark L., Talani G., Lovinger D.M. Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity. Eur J Neurosci 2009, 29:32-41.
64. Tepper J.M., Koos T., Wilson C.J. GABAergic microcircuits in the neostriatum. Trends Neurosci 2004, 27:662-669.
65. Ariano M.A., Cepeda C., Calvert C.R., Flores-Hernandez J., Hernandez-Echeagaray E., Klapstein G.J., Chandler S.H., Aronin N., DiFiglia M., Levine M.S. Striatal potassium channel dysfunction in Huntington's disease transgenic mice. J Neurophysiol 2005, 93:2565-2574.
66. Stein V., Nicoll R.A. GABA generates excitement. Neuron 2003, 37:375-378.
67. Gulledge A.T., Stuart G.J. Excitatory actions of GABA in the cortex. Neuron 2003, 37:299-309.
68. Prigge M., Schneider F., Tsunoda S.P., Shilyansky C., Wietek J., Deisseroth K., Hegemann P. Color-tuned channel rhodopsins for multiwavelength optogenetics. J Biol Chem 2012, 287:31804-31812.
69. Ade K.K., Janssen M.J., Ortinski P.I., Vicini S. Differential tonic GABA conductances in striatal medium spiny neurons. J Neurosci 2008, 28:1185-1197.
70. Santhakumar V., Jones R.T., Mody I. Developmental regulation and neuroprotective effects of striatal tonic GABAA currents. Neuroscience 2010, 167:644-655.
71. Luo R., Janssen M.J., Partridge J.G., Vicini S. Direct and GABA-mediated indirect effects of nicotinic ACh receptor agonists on striatal neurones. J Physiol 2013, 591:203-217.
72. Kreitzer A.C., Malenka R.C. Striatal plasticity and basal ganglia circuit function. Neuron 2008, 60:543-554.
73. Surmeier D.J., Plotkin J., Shen W. Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection. Curr Opin Neurobiol 2009, 19:621-628.
74. Lovinger D.M. Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum. Neuropharmacology 2010, 58:951-961.
75. Glass M., Dragunow M., Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000, 97:505-519.
76. Van Laere K., Casteels C., Dhollander I., Goffin K., Grachev I., Bormans G., Vandenberghe W. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med 2010, 51:1413-1417.
77. Naydenov A.V., Sepers M.D., Swinney K., Raymond L.A., Palmiter R.D., Stella N. Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice. Neurobiol Dis 2014, 71:140-150.
78. Fieblinger T., Graves S.M., Sebel L.E., Alcacer C., Plotkin J.L., Gertler T.S., Chan C.S., Heiman M., Greengard P., Cenci M.A., et al. Cell type-specific plasticity of striatal projection neurons in Parkinsonism and l-DOPA-induced dyskinesia. Nat Commun 2014, 5:5316.
79. Day M., Wokosin D., Plotkin J.L., Tian X., Surmeier D.J. Differential excitability and modulation of striatal medium spiny neuron dendrites. J Neurosci 2008, 28:11603-11614.
80. Plotkin J.L., Day M., Surmeier D.J. Synaptically driven state transitions in distal dendrites of striatal spiny neurons. Nat Neurosci 2011, 14:881-888.
81. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.F., Levine M.S. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol 2001, 86:2667-2677.
82. Heng M.Y., Detloff P.J., Albin R.L. Rodent genetic models of Huntington disease. Neurobiol Dis 2008, 32:1-9.
83. Cepeda C., Cummings D.M., Andre V.M., Holley S.M., Levine M.S. Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms. ASN Neuro 2010, 2:e00033.
84. Lerner R.P., Trejo Martinez L.d.C., Zhu C., Chesselet M.F., Hickey M.A. Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease. Brain Res Bull 2012, 87:571-578.